Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial

被引：0
|
作者：
Huang, W. [1 ]
Han, D. [1 ]
Li, B. [2 ]
Dong, J. [2 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong First Med Univ, Radiotherapy Dept, Affiliated Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1452P
引用
收藏
页码：S902 / S902
页数：1
相关论文
共 50 条
  • [41] Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
    Negrier, Sylvie
    Rioux-Leclercq, Nathalie
    Ferlay, Celine
    Gross-Goupil, Marine
    Gravis, Gwenaelle
    Geoffrois, Lionel
    Chevreau, Christine
    Boyle, Helen
    Rolland, Frederic
    Blanc, Ellen
    Ravaud, Alain
    Dermeche, Slimane
    Flechon, Aude
    Albiges, Laurence
    Perol, David
    Escudier, Bernard
    EUROPEAN JOURNAL OF CANCER, 2020, 129 : 107 - 116
  • [42] Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
    Wu, G.
    Liu, Y.
    Rao, M.
    Han, Y.
    He, K.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S597 - S598
  • [43] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable esophageal squamous carcinoma: an open-label, single-arm study
    Jiang, Bo
    Yang, Xin
    Zhang, Junling
    Huang, Mengli
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.
    Yang, Xiuli
    Meng, Xiangrui
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Wu, Tao
    Chen, Yunfang
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377
  • [46] Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
    Hua, Yijun
    You, Rui
    Wang, Zhiqiang
    Huang, Peiyu
    Lin, Mei
    Ouyang, Yanfeng
    Xie, Yulong
    Zou, Xiong
    Liu, Youping
    Duan, Chongyang
    Liu, Yonglong
    Gu, Chenmei
    Liu, Rongzeng
    Yang, Qi
    Jiang, Rou
    Zhang, Mengxia
    Ding, Xi
    Chen, Siyuan
    Lin, Chao
    Sun, Rui
    Chen, Mingyuan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [47] Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
    Sun, J.
    Enzinger, P.
    Adenis, A.
    Shah, M.
    Kato, K.
    Bennouna, J.
    Doi, T.
    Hawk, N.
    Yu, L.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S352 - S352
  • [48] Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial
    Guo, Ye
    Shi, Mei
    Yang, Ankui
    Feng, Jifeng
    Zhu, Xiaodong
    Choi, Young-Jin
    Hu, Guoqin
    Pan, Jianji
    Hu, Chunhong
    Luo, Rongcheng
    Zhang, Yiping
    Zhou, Liang
    Cheng, Ying
    Luepfert, Christian
    Cai, Junliang
    Shi, yuankai
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (08): : 1081 - 1087
  • [49] Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
    He, Mingming
    Wang, Zhiqiang
    Lu, Jin
    Bai, Yuxian
    Mao, Teng
    Wang, Jun
    Fan, Qingxia
    Zhang, Yiping
    Zhao, Kuaile
    Chen, Zhendong
    Gao, Shegan
    Li, Jiancheng
    Fu, Zhichao
    Gu, Kangsheng
    Liu, Zhihua
    Wu, Lin
    Zhang, Xiaodong
    Feng, Jifeng
    Niu, Zuoxing
    Ba, Yi
    Zhang, Helong
    Liu, Ying
    Zhang, Li
    Min, Xuhong
    Huang, Jing
    Cheng, Ying
    Wang, Dong
    Sheng, Zhen
    Zeng, Wanqin
    Song, Li
    Xu, Rui-Hua
    Luo, Huiyan
    MED, 2024, 5 (09):
  • [50] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
12345